KAKatsumi Aoyagi

Katsumi Aoyagi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katsumi Aoyagi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Chiharu Ohue

    <!--label omitted: 1-->Diagnostic Division, Tonen Corporation, Ohi-Machi, Iruma-Gun, Saitama 356-8505,1 and

    1 shared publication
  • Eiji Tanaka

    <!--label omitted: 2-->Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Nagano 390-8621,2Japan

    1 shared publication
  • H Tsukayama

    Center for Integrative Medicine, Tsukuba University of Technology, 4–12–7 Kasuga, Tsukuba‐city, 305–8521, Japan E‐mail:‐tech.ac.jp

    1 shared publication
  • H Yamashita

    Center for Integrative Medicine, Tsukuba University of Technology, 4–12–7 Kasuga, Tsukuba‐city, 305–8521, Japan E‐mail:‐tech.ac.jp

    1 shared publication
  • Kendo Kiyosawa

    <!--label omitted: 2-->Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Nagano 390-8621,2Japan

    1 shared publication
  • Kumiko Iida

    <!--label omitted: 1-->Diagnostic Division, Tonen Corporation, Ohi-Machi, Iruma-Gun, Saitama 356-8505,1 and

    1 shared publication

Latest Publications

  • Development of a Simple and Highly Sensitive Enzyme Immunoassay for Hepatitis C Virus Core Antigen

    by Katsumi Aoyagi, Chiharu Ohue, Kumiko Iida, Tatsuji Kimura, Eiji Tanaka, Kendo Kiyosawa, Shintaro Yagi

    A highly sensitive enzyme immunoassay (EIA) for the hepatitis C virus (HCV) core antigen (HCVcAg) was developed, and its performance was compared with that of the AMPLICOR HCV test (Roche Molecular Systems). The developed one-step pretreatment method, 30-min incubation of the specimen with a solution containing three different types of detergents (Triton X-100, 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate [CHAPS], and sodium dodecyl sulfate), does not require any special device. Because the interfering anti-core antibody in the sample was sufficiently inactivated by the pretreatment, HCVcAg in the sample could be detected. The immunoreactivity on gel filtration was shifted from void fractions to those corresponding to the molecular mass range from 20 to 25 kDa, which is equal to the estimated molecular mass of HCVcAg, after the pretreatment. By the recovery test with HCVcAg-positive serum, the recovery rate was 93.5 to 106.5%. There was no interference with the EIA by anticoagulants or blood components in the serum. When the cutoff value was tentatively set at 0.5 mU/ml based on the distribution of healthy subjects’ sera, the sera of all healthy subjects ( n = 125) and patients with hepatitis B ( n = 50) were negative. HCVcAg was detected in sera from 57 of 73 individuals (78.1%) with anti-HCV antibody. Similarly, HCV RNA was detected in sera from 59 individuals (80.8%) with the AMPLICOR HCV as the qualitative test (AMPLICOR HCV test) and in sera from 54 individuals (74.0%) by the AMPLICOR HCV Monitor as the quantitative test (AMPLICOR Monitor test). Concentrations of HCVcAg and HCV RNA (measured by the AMPLICOR Monitor test) correlated significantly ( r = 0.8, P < 0.001). On seroconversion panels, HCVcAg was detected during the early stage of infection, when anti-HCV antibodies had not been produced. This assay for HCVcAg is simpler than assays for HCV RNA based on gene technology and shows specificity and sensitivity equivalent to those of the AMPLICOR HCV test.